Andrew Greenstein,Stacie Shepherd,Andreas G. Moraitis
申请号：
US16719701
公开号：
US20200197373A1
申请日:
2019.12.18
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Novel methods for treating cancer include: administering a glucocorticoid receptor modulator (GRM) to a patient, and determining whether or not the expression level of a gene is decreased in comparison with baseline levels of the gene measured in the patient prior to the GRM administration, thereby identifying a patient as being likely to benefit from cancer chemotherapy in conjunction with GRM administration where the expression level of a gene following GRM administration is decreased in comparison with corresponding gene baseline levels； and administering to said identified patient a combination of a GRM and cancer chemotherapy, whereby the cancer is treated in the patient.The GRM may be selected from relacorilant, CORT125281, CORT122928, and CORT113176. The cancer chemotherapy agent may be a taxane. The gene expression level measured may be selected from 50 identified genes, and may be selected from COX2, DUSP1, GSK3b, MCL-1, PIK3CG, RGS-2, SGK1, and STAT3.
